Sr. Columnist at TheStreet, aka the Col. Jessep of biotech/drug stocks. Data Are. I curse. Said one analyst: The likes of Adam Feuerstein attack viciously.
$ANTH b-mod “CHABLIS” study in lupus continues, per DSMB interim analysis conducted this month. Enrollment at 50%.
@amlewis4 Hey! I remember you. You’re young enough to be my son. Please hire me when I need a new job. Thanks for saying hello.
@amlewis4 Thank you. Plenty of biotech investors and Twitter followers already consider me a total joke.
This is how a company describes itself in a PR when it has absolutely zero going on but failure & hopelessness. $TRGT pic.twitter.com/dZ0qvmCOEU
$TRGT may be dismal failure, but I did learn new word from tonight’s PR: Micturition — the act of urinating.
$TRGT TC-5214 overactive bladder drug not so overactive. Study fails, discontinuing program.
RT @zbiotech: $TRGT whiffed yet again
. @willveritas Next VX-661 data is from 12-week study in f508del homozygous patients, but not expected until early next year. $VRTX
A tornado touched down in Boston today so there is a slight chance $TRGT has something positive to announce.
RT @zbiotech: $TRGT halted
Create a free Muck Rack account to customize your profile and upload a portfolio of your